Vijay Kale

Vijay Kale, MPharm, PhD

Associate Professor of Pharmaceutical Sciences

Area of expertise

Pharmacology, Toxicology, Research using clinical data bases, Osteoarthritis

Dr. Kale received a Ph.D. degree in Pharmacology & Toxicology from the University of Louisiana at Monroe, Louisiana, and B.S. & M.S. in Pharmacy degrees from University of Pune, India & Bharati Vidyapeeth Deemed University, Pune, India respectively. Prior to joining Roseman University, Dr. Kale worked as a postdoctoral fellow at School of Pharmacy, University of Connecticut (UCONN), Storrs, Connecticut & at South Carolina College of Pharmacy, Medical University of South Carolina (MUSC), Charleston, South Carolina. In 2010, Dr. Kale joined College of Pharmacy, Roseman University of Health Sciences as Assistant Professor of Pharmaceutical Sciences where he is currently serving as an Associate Professor of Pharmaceutical Sciences.

Dr. Kale is an active member of several organizations including the Society of Toxicology (SOT), the American Society for Pharmacology & Experimental Therapeutics (ASPET), the American Association of Pharmaceutical Sciences (AAPS) and the American Association of Colleges of Pharmacy (AACP). Dr. Kale received number of national and international fellowships and research awards, served/chaired and currently serving on several College of Pharmacy, Roseman University, and various National Scientific Association Committees. Dr. Kale also serves as an item-writer (NAPLEX/PCOA/FPGEE) for National Association of Boards of Pharmacy (NABP).

Dr. Kale’s teaching interest includes several topics in Pharmacology at College of Pharmacy (PHARM D. students), Previously Dr. Kale also taught pharmacology to first and second year Doctor of Dental Medicine (DMD) students at Roseman University College of Dental Medicine.

Dr. Kale is highly motivated and experienced researcher in Pharmacology and Toxicology field. His current research interests include treatment and prevention of osteoarthritis, development of natural product therapeutics based on mitochondrial biogenesis for the treatment & prevention of diabetes and aging, role of metabolism & tissue repair in toxicity, understanding mechanism behind gingival hyperplasia and therapeutic strategies to treat it, and assessment and intervention in pharmacy teaching and learning and knowledge retention.


Doctor of Philosophy (Ph.D.), Concentration-Pharmacology & Toxicology, University of Louisiana at Monroe, LA.

Master of Pharmacy (M. Pharm.), Concentration-Pharmacology, Bharati Vidyapeeth Deemed University, Pune (Distinction, the Top Student).

Bachelor of Pharmacy (B. Pharm.), Concentration-Pharmacy, University of Pune, Pune (First Class).

Healthcare Analytics Certificate Program (SQL, SAS, SAS Enterprise Miner), University of California at Davis (UC Davis).

Research Interests

  • Treatment and prevention of gingival hyperplasia.
  • Treatment and prevention of osteoarthritis.
  • Assessment and intervention in Pharmacy teaching and learning and knowledge retention.
  • Mitochondrial biogenesis and its role in prevention and/or cure for diabetes, obesity and aging.
  • Toxicological consequences of metabolism, drug interactions, reactive intermediate formation and covalent binding.


Society of Toxicology
The American Society for Pharmacology and Experimental Therapeutics
American Association of Pharmaceutical Scientists
American Association of Colleges of Pharmacy
International Society for the Study of Xenobiotic
American Chemical Society


Editorial Board Member: American Diabetes Association’s Journal Clinical Diabetes (01/01/2017-12/31/2018).
Session Chair: Session-“Kidney”, 50th Anniversary-Annual Meeting, Society of Toxicology, 7th March 2011, Washington, DC.
Secretary (2010-2011), Postdoctoral Assembly (PDA), Society of Toxicology.
Chair and Expert Panelist: Webinar-“From postdoc to permanent position: a panel discussion for non-US citizen early scientists”, Postdoctoral Assembly (PDA), Society of Toxicology, 30th Sept 2010.
Research Excellence in Toxicology Award (2007), Association of Scientists of Indian Origin-Society of Toxicology.
Best Poster Presentation Award (2005), South Central Chapter-Society of Toxicology.
 Travel Awards (2005 & 2006) from South Central Chapter-Society of Toxicology & from Society of Toxicology.
Achievement Award (2003), Bharati Vidyapeeth Deemed University, Pune.
Research Fellowship (2000-2002), All India Council of Technical Education, India.
Research Fellowship (2000-2002), Suresh Kare Indoco Foundation, Mumbai, India.

Teaching Subjects

Professional Pharmacy (Pharm D: Pharmacology – ANS, CNS, Endocrine, Antimicrobials, Toxicology
MS in Biomedical Sciences (Graduate): Signal Transduction -Toxicology
Professional dental Program (DMD): Basic Biomedical Science – Pharmacology


1. Thomas M, Fronk F, Gross AJ, Willmore D, Arango A, Higham C, Nguyen V, Lim H, Kale V, McMillan G, Seegmiller RE (2019); Losartan Attenuates Progression of Osteoarthritis in the Synovial Temporomandibular and Knee Joints of a Chondrodysplasia Mouse Model through inhibition of TGF-β1 signaling pathway, Osteoarthritis and Cartilage, 27(4): 676-686.

2. Zhang J, Kale VM, Chen M (2015), Gene Directed Enzyme Prodrug Therapy; The AAPS Journal, 17 (1): 102-110.

3. Jaligama S, Kale VM, Wilbanks MS, Perkins EJ and Meyer SA (2013), Delayed myelosupression with acute exposure to hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) and environmental degradation product hexahydro-1-nitroso-3,5-dinitro-1,3,5-tirazine (MNX) in rats; Toxicol Appl Pharmacol, 266(3):443-51.

4. Kale VM, Hsiao CJ and Boelsterli UA (2010), Nimesulide-induced electrophilic stress activates Nrf2 in human hepatocytes and mice but is not sufficient to induce hepatotoxicity in Nrf2-deficient mice; 5. Kashimshetty R, Desai VG, Kale VM, Lee T, Moland CL, Branham WS, New LS, Chan EC, Younis H and Boelsterli UA (2009), Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity; Toxicol Appl Pharmacol 238 (2): 150-159.

6. Kale VM, Miranda SR, Wilbanks MS and Meyer SA (2008), Comparative cytotoxicity of alachlor, acetochlor and metolachlor herbicides in isolated rat and cryopreserved human hepatocytes; J Bio Mol Toxicol 22 (1): 41-50.

Published Abstracts:

1. Vijay Kale, Kendra Jackson (2021), Effect of Losartan on Patellar Cartilage Volume Among Patients With Knee Osteoarthritis, The FASEB Journal, Vol 35 (S1),

2. Lipovskyte K, Burrows A, Kale VM (2020); Identify effects of phenytoin and losartan on TGF-beta using human gingival fibroblast-1 (HGF-1) cells and establish HGF-1 cell culture as a model to study drug-induced gingival hyperplasia, The FASEB Journal, Vol 34 (S1)

3. Manas Mandal, Erik Jorvig, Vijay Kale, Jeffery Talbot, Rebecca Keel-Jayakumar, Helen C. Park (2018), Student Faculty Partnership in Developing a Leveling Course. American Journal of Pharmaceutical Education 2018; 82 (5) Article 7158

4. Vijay Kale, Sarah Mathew, Mariya Melnik, and Lisa M Danh (2017), Elucidate the Role of TGF-beta in Prevention and Treatment of Gingival Hyperplasia Using HGF-1 Cells, The FASEB Journal 31:1_supplement, lb633-lb633

5. Elizabeth J. Unni, Erin L. Johanson, Vijay Kale, Venkata K. Yellepeddi (2016), Utility of a Pharmacy Student Organization Leadership Retreat., American Journal of Pharmaceutical Education 2016; 80 (5) Article S2

6. Kale VM, Manoi T, Atkinson S, Porter C (2016), Drug interaction of pirfenidone with commonly prescribed pharmaceutical drugs, The FASEB Journal; 30 (1): lb545

7. Kale VM and Radhakrishnan J (2014). Evaluation of Cell Viability and Mitochondrial Protective Effects of Quercetin in Rat L6 Cells. The Toxicologist (Supplement to J. Toxicological Sciences) 138 (1), Abstract # 797 P 205

8. Jaligama S, Kale VM, Wilbanks MS, Perkins EJ and Meyer SA (2013). Bone marrow inflammation precedes hexahydro-1-nitroso-3,5-dinitro-1,3,5-trazine (MNX) induced delayed myelosuppression in rats. The FASEB Journal; 27:888.5

9. Jaligama S, Kale VM, Wilbanks MS, Perkins EJ and Meyer SA (2013). Effect of bone marrow inflammation in hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine (MNX) induced myelosupression in rats; The Toxicologist (Supplement to J. Toxicological Sciences) 132 (1), Abstract # 250

10. Jaligama S, Kale VM, Wilbanks MS, Perkins EJ and Meyer SA (2012). Early hematological effects of hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine (MNX), environmental degradation product of RDX, persist to cause delayed myelosuppression in rats, International Journal of Toxicology, 32 (1): 76, P402